UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 22, 2006

 

CYTORI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

3020 Callan Road, San Diego, California  92121

(Address of principal executive offices, with zip code)

 

(858) 458-0900

(Registrant’s telephone number, including area code)

 

n/a

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02                                             Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

 

On May 22, 2006, our Board of Directors accepted the resignation of Mr. Charles E. Galetto as the Company’s Senior Vice President Finance and Administration, Treasurer, and Principal Accounting Officer, which resignation is effective May 31, 2006. We do not intend to replace this position, and Mr. John W. Townsend will continue in his role as our Controller. Mr. Galetto will provide part-time financial advisory services to the Company through December 15, 2006.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	CYTORI THERAPEUTICS, INC.
Date:  May 26, 2006	By:	/s/        MARK E. SAAD
		Mark E. Saad
		Chief Financial Officer

 

3